Trial · NCT00569582
A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's Syndrome
NCT00569582, Phase 3, Completed, Corcept Therapeutics; results first posted 2012-05-28
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's Syndrome. Trials, record NCT00569582. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00569582
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's Syndrome
- NCT number
- NCT00569582
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 50 participants, actual
- Lead sponsor
- Corcept Therapeutics
- Conditions
- Cushing's Syndrome
- Interventions
- mifepristone
- First posted
- 2007-12-07
- Last updated
- 2013-08-22
- Results first posted
- 2012-05-28
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Improvement in Diabetes and/or Glucose Intolerance. | Baseline to Week 24 | Responder is defined as subject with a decrease greater than or equal to 25% in area under the curve for glucose on 2-hour oral glucose test from baseline to week 24 or last visit, for Cushing's patients with type-2 diabetes mellitus/impaired glucose tolerance. |
| Primary | Decrease in Diastolic Blood Pressure. | Baseline to Week 24 | Responder is defined as subject with a decrease greater than or equal to 5mm Hg in diastolic blood pressure from baseline to week 24 or last visit. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Improvement in Diabetes and/or Glucose Intolerance. | Baseline to Week 24 | Patients with at least 30 days of dosing. | participants | NUMBER |
| PRIMARY | Decrease in Diastolic Blood Pressure. | Baseline to Week 24 | participants | NUMBER |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Improvement in Diabetes and/or Glucose Intolerance. | Mifepristone | 15 | participants | ||
| Decrease in Diastolic Blood Pressure. | Mifepristone | 8 | participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Mifepristone | 50 | |
| Overall Study | COMPLETED | Mifepristone | 34 | |
| Overall Study | NOT COMPLETED | Mifepristone | 16 |
Source ClinicalTrials.gov
Adverse events72
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Nausea | Gastrointestinal disorders | Mifepristone | 24 | 50 | 40 |
| other | Vomiting | Gastrointestinal disorders | Mifepristone | 13 | 50 | 21 |
| other | Dry mouth | Gastrointestinal disorders | Mifepristone | 9 | 50 | 12 |
| other | Diarrhoea | Gastrointestinal disorders | Mifepristone | 6 | 50 | 8 |
| other | Constipation | Gastrointestinal disorders | Mifepristone | 5 | 50 | 5 |
| other | Gastrooesophageal reflux disease | Gastrointestinal disorders | Mifepristone | 4 | 50 | 4 |
| other | Fatigue | General disorders | Mifepristone | 24 | 50 | 37 |
| other | Oedema peripheral | General disorders | Mifepristone | 13 | 50 | 31 |
| other | Pain | General disorders | Mifepristone | 7 | 50 | 9 |
| other | Asthenia | General disorders | Mifepristone | 3 | 50 | 5 |
1 to 10 of 72Source ClinicalTrials.gov
See all 72 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Mifepristone | ||
| Total, other adverse events | Mifepristone | 49 | 50 |
| Total, serious adverse events | Mifepristone | 16 | 50 |
Source ClinicalTrials.gov
Papers11
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00569582
GET https://conductscience.org/api/trials/v1/NCT00569582/events?page=2